Explore the Performance of IntelliCap.

NCT ID: NCT02025348

Last Updated: 2016-01-27

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: EARLY_PHASE1
• Total Enrollment: 20 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2014-01-31
• Study Completion Date: 2014-03-31

Brief Summary

This is an open-label, randomised, 4-way crossover study in twelve healthy male volunteers.

The study will characterise the performance of IntelliCap® by evaluating the plasma concentration and pharmacokinetic profile of a probe drug (IMP; metoprolol) released from IntelliCap® with three different release profiles and the plasma concentration and pharmacokinetic profile of the same probe drug after a single dose of an oral solution.

Conditions

Plasma Concentration; Pharmacokinetic Profile

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: BASIC_SCIENCE
• Blinding Strategy: NONE

Study Groups

Treatment A metoprolol 50mg

IntelliCap® capsule Release profile 1 filled with metoprolol gastroenteral solution 233 mg/mL (dose 50 mg).

Group Type: EXPERIMENTAL

IntelliCap

Intervention Type: DRUG

Drug release from the IntelliCap® system will be actuated post-gastric emptying of IntelliCap® capsule.

Treatment B metoprolol 50mg

IntelliCap® capsule Release profile 2 filled with metoprolol gastroenteral solution 233 mg/mL (dose 50 mg).

Group Type: EXPERIMENTAL

IntelliCap

Intervention Type: DRUG

Drug release from the IntelliCap® system will be actuated post-gastric emptying of IntelliCap® capsule.

Treatment C metoprolol 50mg

IntelliCap® capsule Release profile 3 filled with metoprolol gastroenteral solution 233 mg/mL (dose 50 mg).

Group Type: EXPERIMENTAL

IntelliCap

Intervention Type: DRUG

Drug release from the IntelliCap® system will be actuated post-gastric emptying of IntelliCap® capsule.

Treatment D metorpolol 50mg

metoprolol oral solution 1 mg/mL (dose 50 mg).

Group Type: EXPERIMENTAL

IntelliCap

Intervention Type: DRUG

Drug release from the IntelliCap® system will be actuated post-gastric emptying of IntelliCap® capsule.

Interventions

IntelliCap

Drug release from the IntelliCap® system will be actuated post-gastric emptying of IntelliCap® capsule.

Intervention Type: DRUG

Other Intervention Names

IntelliCap and metoprolol

Eligibility Criteria

Inclusion Criteria

• Healthy male volunteers aged between 18 and 50 years of age, inclusive.
• Subjects with a body weight of at least 50 kg and no more than 100 kg, inclusive.
• Subjects with a body mass index (BMI) of 18 - 30 kg/m2, inclusive. BMI = Body weight (kg) / [Height (m)]2.
• Subjects with suitable veins for cannulation or repeated venepuncture.
• Subjects must be available to complete the study.
• Subjects must satisfy a medical examiner about their fitness to participate in the study.
• Subjects must provide written informed consent to participate in the study.

Exclusion Criteria

• History of any clinically important disease or disorder which, in the opinion of the Investigator, may either put the subject at risk because of participation in the study, or influence the results or the subject's ability to participate in the study.
• Abnormal vital signs, after 10 min supine rest, defined as any of the following:
• Systolic blood pressure < 100 mmHg or ≥ 140 mmHg.
• Diastolic blood pressure < 50 mmHg or ≥ 90 mmHg.
• Heart rate < 50 or > 85 beats per minute.
• Any clinically important abnormalities in rhythm, conduction or morphology of the resting ECG.
• History of severe allergy/hypersensitivity or on-going clinically important allergy/ hypersensitivity as judged by the Investigator or known hypersensitivity to metoprolol (including other beta-blockers) or any other component of the product.

•Plasma donation within one month of screening or any blood donation/blood loss greater than 500 mL during the three (3) months prior to screening.

• Receipt of a new chemical entity (defined as a compound which has not been approved for marketing) or participation in any other clinical study that includes drug treatment within at least three (3) months of the first administration of study treatment in this study. The period of exclusion begins three months after the final dose. Note: subjects consented and screened, but not randomised in this study or a previous phase I study, are not excluded.
• Previous randomisation to treatment in the present study.
• Involvement of any CRO/third party contractor or AZ employee and their close relatives regardless of their role.
• Judgement by the Investigator that the subject should not participate in the study if they have any on-going or recent (i.e., during the screening period) minor medical complaints that may interfere with the interpretation of study data or are considered unlikely to comply with study procedures, restrictions and requirements.
• Subjects who cannot communicate reliably with the Investigator.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 50 Years
• Eligible Sex: MALE
• Accepts Healthy Volunteers: Yes

Sponsors

AstraZeneca

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Salvatore Febbraro, MD PhD

Role: PRINCIPAL_INVESTIGATOR

Simbec Research

Locations

Research Site

Merthyr Tydfil, , United Kingdom

Countries

United Kingdom

Related Links

http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&studyid=2726&filename=D1840M00044_CSR_Synopsis.pdf

D1840M00044\_CSR\_Synopsis

http://www.ncbi.nlm.nih.gov/pubmed/26385166

Publication

Other Identifiers

D1840M00044

Identifier Type: -

Identifier Source: org_study_id